AzTrials
AzTrials

Herpes ZosterNCT01772160

Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy

An observational study of Herpes Zoster and Herpes Zoster Vaccine, run by GlaxoSmithKline at 43 sites in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to collect data on the incidence, complications, economic burden and impact on the quality of life in adults aged ≥ 50 years with HZ disease in Italy. Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
Herpes Zoster, Herpes Zoster Vaccine
What is being tested?
Data collection
How many people
395 participants
Where
43 sitesItaly
Study dates
26 Feb 2013to 5 Oct 2016
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult population, male or female aged ≥ 50 years of age presenting with a HZ episode.

Who may be able to join

  • A male or female ≥ 50 years of age at the time of study enrolment presenting with acute HZ.
  • HZ diagnosis for this HZ episode:
  • Is his/her first outpatient diagnosis (i.e. initial consultation), OR
  • Took place at another site/centre (e.g. emergency room or Dermatologist/Specialist practice) provided the HZ diagnosis is not more than 7 days before the initial visit for the present study (i.e. secondary consultation).
  • Written informed consent obtained from the patient.
  • Ability to comply with study procedures.

Who cannot join

  • Patient participating in another clinical study (participation in another observational, non-interventional trial is allowed).

Trial locations and contacts

43 sites in 1 country.

43 sites in 1 country

Italy43 sites
  • GSK Investigational Site

    Alessandria, Piedmont, 15121

  • GSK Investigational Site

    Alessano (LE)

  • GSK Investigational Site

    Angera (VA), Lombardy

  • GSK Investigational Site

    Arcidosso (GR), Tuscany, 58031

  • GSK Investigational Site

    Arcisate (VA), Lombardy, 21051

  • GSK Investigational Site

    Arezzo, Tuscany, 52100

  • GSK Investigational Site

    Cavallino (LE), Apulia, 73020

  • GSK Investigational Site

    Civitella Paganico (GR), Tuscany, 58045

  • GSK Investigational Site

    Comerio (VA), Lombardy, 21020

  • GSK Investigational Site

    Copertino (LE), Apulia, 73043

  • GSK Investigational Site

    Cutrofiano (LE), Apulia, 73020

  • GSK Investigational Site

    Fagnano Olona (VA), Lombardy, 21054

  • GSK Investigational Site

    Follonica (GR), Tuscany, 58022

  • GSK Investigational Site

    Frugarolo (AL), Piedmont, 15065

  • GSK Investigational Site

    Galatina (LE), Apulia, 73013

  • GSK Investigational Site

    Ghirla Valganna (VA), Lombardy, 21030

  • GSK Investigational Site

    Grosseto, Tuscany, 58100

  • GSK Investigational Site

    Induno Olona (VA), Lombardy, 21040

  • GSK Investigational Site

    Lucignano (AR), Tuscany, 52046

  • GSK Investigational Site

    Montesano S. (LE), Apulia, 73035

  • GSK Investigational Site

    Naples, Campania, 80125

  • GSK Investigational Site

    Naples, Campania, 80126

  • GSK Investigational Site

    Orbetello (GR), Tuscany, 58015

  • GSK Investigational Site

    Oviglio (AL), Piedmont, 15026

  • GSK Investigational Site

    Parabita (LE), Apulia, 73052

  • GSK Investigational Site

    Perugia, Umbria, 06125

  • GSK Investigational Site

    Perugia, Umbria, 06126

  • GSK Investigational Site

    Perugia, Umbria

  • GSK Investigational Site

    Ripa (PG), Umbria, 06134

  • GSK Investigational Site

    Rome, Lazio, 00141

  • GSK Investigational Site

    Rome, Lazio, 00142

  • GSK Investigational Site

    Rome, Lazio, 00144

  • GSK Investigational Site

    Rome, Lazio, 00162

  • GSK Investigational Site

    Rome, Lazio, 00176

  • GSK Investigational Site

    Rome, Lazio, 00197

  • GSK Investigational Site

    Rome, 00144

  • GSK Investigational Site

    Sale (AL), Piedmont, 15045

  • GSK Investigational Site

    Sassofortino (GR), Tuscany, 58029

  • GSK Investigational Site

    Sesto Calende (VA), Lombardy, 21018

  • GSK Investigational Site

    Solbiate Olona (VA), Lombardy, 21052

  • GSK Investigational Site

    Specchia (LE), Apulia, 73040

  • GSK Investigational Site

    Varese, Lombardy, 21100

  • GSK Investigational Site

    Villalvernia (AL), Piedmont, 15050

Other trials in Italy

About this study

Official title: Population Based Surveillance to Estimate the Burden of Herpes Zoster and Post-herpetic Neuralgia in Italy

The purpose of this study is to collect data on the incidence, complications, economic burden and impact on the quality of life in adults aged ≥ 50 years with HZ disease in Italy.

Read the detailed description

The surveillance/recruitment period will take approximately 2 years and once the enrolment of HZ patients has ended, the study will continue for a maximum of 9 months to allow for completion of the follow-up of potential PHN cases.

The data will be captured at protocol specified time-points based on the time of enrolment of each subject.

Being tested
Data collection
Keywords
Adults, Italy, Herpes Zoster, Complications, Quality of life, Surveillance, Burden, Cost, Incidence
Medical subject headings
Herpes Zoster

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Data collectionOther

    HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.

Study groups in NCT01772160
Study groupRoleWhat they receive
Herpes Zoster GroupMale or female subjects aged 50 years or above, presenting with a herpes zoster (HZ) episode.
Receives: Other: Data collection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender

    A case of HZ was defined as new unilateral pain (broadly defined to include allodynia and pruritus) accompanied by unilateral rash and no alternative diagnosis. Age ranges were 50-54, 55-59, 60-64, 65-69, 70-74, 75-79 and greater than or equal to (≥) 80 years. The incidence rate was expressed as the number of HZ cases per (/) 1000 person-years.

    Measured: Day 0 to 2 years

Secondary outcomes (16)
  1. Percentage of Postherpetic Neuralgia (PHN) Cases Among HZ, Overall

    PHN persistence refers to pain occurring or persisting from Day 90 to Day 270 after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'.

    Measured: At Day 90, 180 and 270 after onset of HZ

  2. General Medical History of Cases With HZ, Overall

    General medical history focused on characteristics such as patient pre-existing condition and diseases (local trauma, diabetes mellitus, liver disease, alcoholism, renal failure/dialysis, emotional problems, stress or depression, blood malignancy, solid malignancy, hematopoetic cell/ bone marrow transplant, solid organ transplantation, HIV infection, hepatitis C under active therapy, autoimmune disease active and under therapy, other).

    Measured: Between Day 0 and Day 270.

  3. Other General Medical History Characteristics for HZ Cases, Overall

    Other general medical history characteristics referred to arterial problems, cerebral problems, gastric problems, gastric problems, prostate problems (arterial hypertension and allergic rhinitis, arterial hypertension and pacemaker, arteriopathy and past nun-Hodgkin lymphoma, atrial fibrillation, bronchopathy, cerebral thrombosis, cholecyst, chronic cerebral ischemia, chronic leukemia, chronic obstructive pulmonary disease, epilepsy, gastric lymphoma, gastropathy, hypertension, hypertension and hypothyroidism after surgery, hypertension dyslipidemia and hyperthyroidism, hypothyroidism hypertension, polycythaemia, polycythaemia from 10 years, prostate neoplasm, prostate oral anticoagulant therapy cardiopathy, prostatic cancer, right feet arthralgia, thrombocytopenia, vasculopathy chronic brain).

    Measured: Between Day 0 and Day 270.

  4. Clinical Information of Cases With HZ, Overall

    Clinical information of HZ cases referred to experience of any symptoms before rash, actual symptoms before rash (SBR), any complications at initial visit.

    Measured: Between Day 0 and Day 270

  5. Complications Related to HZ Cases, Overall

    HZ related complications refer to cutaneous complications (Varicella Zoster Virus [VZV] dissemination, Bacterial superinfection), ocular (Loss of corneal sensation, Keratitis, Scleritis, Uveitis, Iridocyclitis), neurological (Meningo-encephalitis, Cranial nerve palsies, Peripheral nerve palsies, Ramsay-Hunt syndrome, Persistent HZ-related Pain), visceral [Neural extension of VZV infection (bronchitis, esophagitis,cystitis), VZV dissemination (pneumonia, arthritis, hepatitis] and other.

    Measured: Between Day 0 and Day 270

  6. Other Complications Related to HZ Cases, Overall

    HZ related other complications refer to axillary lympagenopathy, burning sensation, hypoacusis, itching and rectum pain.

    Measured: Between Day 0 and Day 270

  7. Direct Medical Costs, Direct Non-medical Costs and Indirect Costs

    Cost data related to HZ included medication, procedures and referral to hospital/specialist for direct medical costs, transport for direct non-medical costs and missed time from work, sick certificate for the indirect costs.

    Measured: Up to Day 90

  8. Worst Pain Assessment in HZ Subjects

    The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.

    Measured: At Day 90

  9. Average Pain Assessment in HZ Subjects

    The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.

    Measured: At Day 90

  10. Impact of HZ on Quality of Life as Assessed by the Zoster Pain Inventory

    PHN persistence refers to pain occurring or persisting between 90-270 days after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'.

    Measured: At Day 0, 15, 30, 60, 90

  11. Impact of HZ on Quality of Life as Assessed by the EuroQoL-Five Digits

    EuroQoL-Five Digits (EQ-5D) is a standardised instrument for use as a measure of health outcome and is designed for self-completion by respondents. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index/scale goes from 0 (worst health state) to 1 (perfect health state).

    Measured: At Day 0, 15, 30, 60, 90

  12. PHN Direct Medical Costs, Direct Non-medical Costs and Indirect Costs by Payer/Societal Perspective

    Cost data related to HZ included medication, procedures and referral to hospital/specialist for direct medical costs, transport for direct non-medical costs and missed time from work, sick certificate for the indirect costs.

    Measured: Between Day 90 and Day 270

  13. Worst Pain Assessment in PHN Subjects

    The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.

    Measured: At Day 90

  14. Average Pain Assessment in PHN Subjects

    The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. The ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.

    Measured: At Day 90

  15. Impact of PHN on Quality of Life as Assessed by the Zoster Pain Inventory

    PHN persistence refers to pain occurring or persisting between 90-270 days after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'.

    Measured: At Day 0, 15, 30, 60, 90

  16. Impact of PHN on Quality of Life as Assessed by the EuroQoL-Five Digits

    EuroQoL-Five Digits (EQ-5D) is a standardised instrument for use as a measure of health outcome and is designed for self-completion by respondents. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was 0 (worst health state) to 1 (best health state).

    Measured: At Day 0, 15, 30, 60, 90

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2013 (estimated)
  2. Study start26 Feb 2013
  3. Primary completion5 Oct 2016
  4. Study completion5 Oct 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
395 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01772160
Sponsor's protocol ID
116208
Status last verified
May 2020
First submitted
17 Jan 2013
Last updated
22 May 2020
Individual data sharing
Yes: IPD for this study will be made available via the Clinical Study Data Request site.

Publications

  • Salvetti A, Ferrari V, Garofalo R, Gazzaniga P, Guerroni A, Metrucci A, Sessa A, Severi ML, Nati G, Ruggeri M, Rossi A, Cappellari L, Gopala K, Tosatto R, Simone B. Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged >/=50 years: A prospective study. Prev Med Rep. 2019 Apr 24;14:100882. doi: 10.1016/j.pmedr.2019.100882. eCollection 2019 Jun.

    PubMed 31193254
  • Matthews S, De Maria A, Passamonti M, Ristori G, Loiacono I, Puggina A, Curran D. The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy. Open Forum Infect Dis. 2019 Jan 12;6(2):ofz007. doi: 10.1093/ofid/ofz007. eCollection 2019 Feb.

    PubMed 30793003

Questions about this trial

What is this clinical trial studying?

An observational study of Herpes Zoster and Herpes Zoster Vaccine, run by GlaxoSmithKline at 43 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 43 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 May 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender (time frame: Day 0 to 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01772160, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in